The genetics of drug-induced QT prolongation: evaluating the evidence for pharmacodynamic variants

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Roden DM. Drug-induced prolongation of the QT interval. N. Engl. J. Med. 350(10), 1013–1022 (2004).
  Medline CASGoogle Scholar
• 2. Zhang Y, Post WS, Dalal D et al. QT-interval duration and mortality rate: results from the Third National Health and Nutrition Examination Survey. Arch. Intern. Med. 171(19), 1727–1733 (2011).
  MedlineGoogle Scholar
• 3. Zhang Y, Post WS, Blasco-Colmenares E et al. Electrocardiographic QT interval and mortality: a meta-analysis. Epidemiology 22(5), 660–670 (2011).
  MedlineGoogle Scholar
• 4. Rautaharju PM, Surawicz B, Gettes LS et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. Circulation 119(10), e241–250 (2009).
  MedlineGoogle Scholar
• 5. Schwartz PJ, Ackerman MJ. The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy. Eur. Heart J. 34(40), 3109–3116 (2013).
  MedlineGoogle Scholar
• 6. Drew BJ, Ackerman MJ, Funk M et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J. Am. Coll. Cardiol. 55(9), 934–947 (2010).
  MedlineGoogle Scholar
• 7. Sauer AJ, Moss AJ, McNitt S et al. Long QT syndrome in adults. J. Am. Coll. Cardiol. 49(3), 329–337 (2007).
  MedlineGoogle Scholar
• 8. Arizona Center for Education and Research on Therapeutics. QTdrugs List. www.crediblemeds.org
  Google Scholar
• 9. Fermini B, Fossa AA. The impact of drug-induced QT interval prolongation on drug discovery and development. Nat. Rev. Drug Discov. 2(6), 439–447 (2003).
  Medline CASGoogle Scholar
• 10. Schmitt N, Grunnet M, Olesen SP. Cardiac potassium channel subtypes: new roles in repolarization and arrhythmia. Physiol. Rev. 94(2), 609–653 (2014).
  Medline CASGoogle Scholar
• 11. Dhamoon AS, Jalife J. The inward rectifier current (IK1) controls cardiac excitability and is involved in arrhythmogenesis. Heart Rhythm 2(3), 316–324 (2005).
  MedlineGoogle Scholar
• 12. Aronsen JM, Swift F, Sejersted OM. Cardiac sodium transport and excitation–contraction coupling. J. Mol. Cell Cardiol. 61, 11–19 (2013).
  Medline CASGoogle Scholar
• 13. Estes SI, Ye D, Zhou W et al. Characterization of the CACNA1C-R518C missense mutation in the pathobiology of long-QT syndrome using human induced pluripotent stem cell cardiomyocytes shows action potential prolongation and L-type calcium channel perturbation. Circ. Genom. Precis. Med. 12(8), e002534 (2019).
  Medline CASGoogle Scholar
• 14. Roden DM. A current understanding of drug-induced QT prolongation and its implications for anticancer therapy. Cardiovasc. Res. 115(5), 895–903 (2019).
  Medline CASGoogle Scholar
• 15. Del Camino D, Holmgren M, Liu Y, Yellen G. Blocker protection in the pore of a voltage-gated K+ channel and its structural implications. Nature 403(6767), 321–325 (2000).
  MedlineGoogle Scholar
• 16. Mitcheson JS, Chen J, Lin M et al. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U. S. A. 97(22), 12329–12333 (2000).
  Medline CASGoogle Scholar
• 17. Wang W, MacKinnon R. Cryo-EM structure of the open human ether-à-go-go-related K(+) channel hERG. Cell 169(3), 422–430.e410 (2017).
  Medline CASGoogle Scholar
• 18. Ficker E, Kuryshev YA, Dennis AT et al. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol. Pharmacol. 66(1), 33–44 (2004).
  Medline CASGoogle Scholar
• 19. Roden DM. Taking the ‘idio’ out of ‘idiosyncratic’: predicting torsades de pointes. Pacing Clin. Electrophysiol. 21(5), 1029–1034 (1998). •• Proposes the concept of ‘repolarization reserve' to explain the complexity of the repolarization phase of the action potential and the mechanism associated with diLQTS.
  Medline CASGoogle Scholar
• 20. Volders PG, Sipido KR, Vos MA et al. Downregulation of delayed rectifier K(+) currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes. Circulation 100(24), 2455–2461 (1999).
  Medline CASGoogle Scholar
• 21. Lengyel C, Dézsi L, Biliczki P et al. Effect of a neuroprotective drug, eliprodil on cardiac repolarisation: importance of the decreased repolarisation reserve in the development of proarrhythmic risk. Br. J. Pharmacol. 143(1), 152–158 (2004).
  Medline CASGoogle Scholar
• 22. Gallacher DJ, Van De Water A, Van Der Linde H et al. In vivo mechanisms precipitating torsades de pointes in a canine model of drug-induced long-QT1 syndrome. Cardiovasc. Res. 76(2), 247–256 (2007).
  Medline CASGoogle Scholar
• 23. Kaab S, Crawford DC, Sinner MF et al. A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ. Cardiovasc. Genet. 5(1), 91–99 (2012). • Shows in a large candidate gene study that KCNE1 D85N is associated with diLQTS risk.
  MedlineGoogle Scholar
• 24. Niemeijer MN, Van Den Berg ME, Eijgelsheim M et al. Pharmacogenetics of drug-induced QT interval prolongation: an update. Drug Saf. 38(10), 855–867 (2015).
  Medline CASGoogle Scholar
• 25. Itoh H, Crotti L, Aiba T et al. The genetics underlying acquired long QT syndrome: impact for genetic screening. Eur. Heart J. 37(18), 1456–1464 (2016). •• Shows that the prevalence of cLQTS mutations have only been identified in a minority of diLQTS cases.
  MedlineGoogle Scholar
• 26. Moss AJ, Schwartz PJ. Delayed repolarization (QT or QTU prolongation) and malignant ventricular arrhythmias. Mod. Concepts Cardiovasc. Dis. 51(3), 85–90 (1982).
  Medline CASGoogle Scholar
• 27. Roden DM, Glazer AM, Kroncke B. Arrhythmia genetics: not dark and lite, but 50 shades of gray. Heart Rhythm 15(8), 1231–1232 (2018).
  MedlineGoogle Scholar
• 28. Adler A, Novelli V, Amin AS et al. An international, multicentered, evidence-based reappraisal of genes reported to cause congenital long QT syndrome. Circulation 141(6), 418–428 (2020). •• Developed a semiquantitative scoring system to evaluate the level of evidence for 17 genes reported to cause cLQTS. It was found that only three genes (KCNQ1, KCNH2 and SCN5A) were curated as definitive genes for typical LQTS.
  Medline CASGoogle Scholar
• 29. Buniello A, Macarthur JaL, Cerezo M et al. The NHGRI-EBI GWAS catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 47(D1), D1005–d1012 (2019).
  Medline CASGoogle Scholar
• 30. Hosseini SM, Kim R, Udupa S et al. Reappraisal of reported genes for sudden arrhythmic death: evidence-based evaluation of gene validity for Brugada syndrome. Circulation 138(12), 1195–1205 (2018).
  MedlineGoogle Scholar
• 31. Walsh R, Adler A, Amin AS et al. Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death. Eur. Heart J. 43(15), 1500–1510 (2022).
  MedlineGoogle Scholar
• 32. Caudle KE, Klein TE, Hoffman JM et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr. Drug Metab. 15(2), 209–217 (2014).
  Medline CASGoogle Scholar
• 33. Karczewski KJ, Francioli LC, Tiao G et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581(7809), 434–443 (2020).
  Medline CASGoogle Scholar
• 34. Kang C, Tian C, Sönnichsen FD et al. Structure of KCNE1 and implications for how it modulates the KCNQ1 potassium channel. Biochemistry 47(31), 7999–8006 (2008).
  Medline CASGoogle Scholar
• 35. Zheng R, Thompson K, Obeng-Gyimah E et al. Analysis of the interactions between the C-terminal cytoplasmic domains of KCNQ1 and KCNE1 channel subunits. Biochem. J. 428(1), 75–84 (2010).
  Medline CASGoogle Scholar
• 36. Sakata S, Kurata Y, Li P et al. Instability of KCNE1-D85N that causes long QT syndrome: stabilization by verapamil. Pacing Clin. Electrophysiol. 37(7), 853–863 (2014).
  MedlineGoogle Scholar
• 37. Nishio Y, Makiyama T, Itoh H et al. D85N, a KCNE1 polymorphism, is a disease-causing gene variant in long QT syndrome. J. Am. Coll. Cardiol. 54(9), 812–819 (2009).
  Medline CASGoogle Scholar
• 38. Du C, El Harchi A, Zhang H, Hancox JC. Modification by KCNE1 variants of the hERG potassium channel response to premature stimulation and to pharmacological inhibition. Physiol. Rep. 1(6), e00175 (2013).
  MedlineGoogle Scholar
• 39. Westenskow P, Splawski I, Timothy KW et al. Compound mutations: a common cause of severe long-QT syndrome. Circulation 109(15), 1834–1841 (2004).
  MedlineGoogle Scholar
• 40. Nof E, Barajas-Martinez H, Eldar M et al. LQT5 masquerading as LQT2: a dominant negative effect of KCNE1-D85N rare polymorphism on KCNH2 current. Europace 13(10), 1478–1483 (2011).
  MedlineGoogle Scholar
• 41. Marstrand P, Christensen AH, Bartels ED, Theilade J. Citalopram and the KCNE1 D85N variant: a case report on the implications of a genetic modifier. Eur. Heart J. Case Rep. 2(4), yty106 (2018).
  MedlineGoogle Scholar
• 42. Lin L, Horigome H, Nishigami N et al. Drug-induced QT-interval prolongation and recurrent torsade de pointes in a child with heterotaxy syndrome and KCNE1 D85N polymorphism. J. Electrocardiol. 45(6), 770–773 (2012).
  MedlineGoogle Scholar
• 43. Paulussen AD, Gilissen RA, Armstrong M et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J. Mol. Med. (Berl). 82(3), 182–188 (2004).
  Medline CASGoogle Scholar
• 44. Martinez-Matilla M, Blanco-Verea A, Santori M et al. Genetic susceptibility in pharmacodynamic and pharmacokinetic pathways underlying drug-induced arrhythmia and sudden unexplained deaths. Forensic Sci. Int. Genet. 42, 203–212 (2019).
  Medline CASGoogle Scholar
• 45. Weeke P, Mosley JD, Hanna D et al. Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome. J. Am. Coll. Cardiol. 63(14), 1430–1437 (2014). •• Shows that rare variants are associated with drug-induced long QT interval syndrome and torsades de pointes. This whole-exome study discovered that rare variants in KCNE1 and ACN9 genes are associated with diLQTS risk.
  Medline CASGoogle Scholar
• 46. Nielsen NH, Winkel BG, Kanters JK et al. Mutations in the Kv1.5 channel gene KCNA5 in cardiac arrest patients. Biochem. Biophys. Res. Commun. 354(3), 776–782 (2007).
  Medline CASGoogle Scholar
• 47. Corponi F, Fabbri C, Boriani G et al. Corrected QT interval prolongation in psychopharmacological treatment and its modulation by genetic variation. Neuropsychobiology 77(2), 67–72 (2019).
  MedlineGoogle Scholar
• 48. Spellmann I, Reinhard MA, Veverka D et al. QTc prolongation in short-term treatment of schizophrenia patients: effects of different antipsychotics and genetic factors. Eur. Arch. Psychiatry Clin. Neurosci. 268(4), 383–390 (2018).
  MedlineGoogle Scholar
• 49. Behr ER, Ritchie MD, Tanaka T et al. Genome wide analysis of drug-induced torsades de pointes: lack of common variants with large effect sizes. PLoS One 8(11), e78511 (2013).
  Medline CASGoogle Scholar
• 50. Avery CL, Sitlani CM, Arking DE et al. Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval. Pharmacogenomics J 14(1), 6–13 (2014).
  Medline CASGoogle Scholar
• 51. Chevalier P, Rodriguez C, Bontemps L et al. Non-invasive testing of acquired long QT syndrome: evidence for multiple arrhythmogenic substrates. Cardiovasc. Res. 50(2), 386–398 (2001).
  Medline CASGoogle Scholar
• 52. Makita N, Horie M, Nakamura T et al. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation 106(10), 1269–1274 (2002).
  MedlineGoogle Scholar
• 53. Itoh H, Sakaguchi T, Ding WG et al. Latent genetic backgrounds and molecular pathogenesis in drug-induced long-QT syndrome. Circ. Arrhythm. Electrophysiol. 2(5), 511–523 (2009).
  Medline CASGoogle Scholar
• 54. Aberg K, Adkins DE, Liu Y et al. Genome-wide association study of antipsychotic-induced QTc interval prolongation. Pharmacogenomics J. 12(2), 165–172 (2012).
  Medline CASGoogle Scholar
• 55. Zerdazi EH, Vorspan F, Marees AT et al. QT length during methadone maintenance treatment: gene x dose interaction. Fundam. Clin. Pharmacol. 33(1), 96–106 (2019).
  Medline CASGoogle Scholar
• 56. Roberts JD, Krahn AD, Ackerman MJ et al. Loss-of-function KCNE2 variants: true monogenic culprits of long-QT syndrome or proarrhythmic variants requiring secondary provocation? Circ. Arrhythm. Electrophysiol. 10(8), e005282 (2017).
  Medline CASGoogle Scholar
• 57. Volpi S, Heaton C, Mack K et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol. Psychiatry 14(11), 1024–1031 (2009). • This genome-wide association study shows that common variants that nothing have to do with ion channel function, may also predispose to diLQTS.
  Medline CASGoogle Scholar
• 58. Floyd JS, Sitlani CM, Avery CL et al. Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group. Pharmacogenomics J. 18(1), 127–135 (2018).
  Medline CASGoogle Scholar
• 59. Abbott GW, Sesti F, Splawski I et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97(2), 175–187 (1999).
  Medline CASGoogle Scholar
• 60. Sesti F, Abbott GW, Wei J et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc. Natl. Acad. Sci. USA 97(19), 10613–10618 (2000).
  Medline CASGoogle Scholar
• 61. Sanchez O, Campuzano O, Fernández-Falgueras A et al. Natural and undetermined sudden death: value of post-mortem genetic investigation. PLoS One 11(12), e0167358 (2016).
  MedlineGoogle Scholar
• 62. Jain A SJQ. Quinidine. In: StatPearls. StatPearls Publishing, FL, USA (2021).
  Google Scholar
• 63. Richards S, Aziz N, Bale S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17(5), 405–424 (2015).
  MedlineGoogle Scholar
• 64. Giudicessi JR, Roden DM et al. Classification and reporting of potentially proarrhythmic common genetic variation in long QT syndrome genetic testing. Circulation 137(6), 619–630 (2018).
  Medline CASGoogle Scholar
• 65. Linskey DW, Linskey DC, Mcleod HL, Luzum JA. The need to shift pharmacogenetic research from candidate gene to genome-wide association studies. Pharmacogenomics 22(17), 1143–1150 (2021).
  CASGoogle Scholar
• 66. Ramirez AH, Shaffer CM, Delaney JT et al. Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. Pharmacogenomics J. 13(4), 325–329 (2013).
  Medline CASGoogle Scholar
• 67. Schildcrout JS, Denny JC, Bowton E et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin. Pharmacol. Ther. 92(2), 235–242 (2012).
  Medline CASGoogle Scholar
• 68. Klein ME, Parvez MM, Shin JG. Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions. J. Pharm. Sci. 106(9), 2368–2379 (2017).
  Medline CASGoogle Scholar
• 69. Luzum JA, Pakyz RE, Elsey AR et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: outcomes and metrics of pharmacogenetic implementations across diverse healthcare systems. Clin. Pharmacol. Ther. 102(3), 502–510 (2017).
  Medline CASGoogle Scholar
• 70. Relling MV, Altman RB, Goetz MP, Evans WE. Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol. 11(6), 507–509 (2010).
  MedlineGoogle Scholar
• 71. Luzum JA, Cheung JC. Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations. Pharmacogenomics 19(15), 1203–1216 (2018).
  CASGoogle Scholar
• 72. Pirmohamed M, Hughes DA. Pharmacogenetic tests: the need for a level playing field. Nat. Rev. Drug Discov. 12(1), 3–4 (2013).
  Medline CASGoogle Scholar
• 73. Khoury MJ. Dealing with the evidence dilemma in genomics and personalized medicine. Clin. Pharmacol. Ther. 87(6), 635–638 (2010).
  Medline CASGoogle Scholar
• 74. Luzum JA, Petry N, Taylor AK et al. Moving pharmacogenetics into practice: it's all about the evidence! Clin. Pharmacol. Ther. 110(3), 649–661 (2021).
  MedlineGoogle Scholar
• 75. Koch BC, Van Schaik RH, Van Gelder T, Mathijssen RH. Doubt about the feasibility of preemptive genotyping. Clin. Pharmacol. Ther. 93(3), 233 (2013).
  Medline CASGoogle Scholar
• 76. Nissen SE. Pharmacogenomics and clopidogrel: irrational exuberance? JAMA 306(24), 2727–2728 (2011).
  Medline CASGoogle Scholar
• 77. Strauss DG, Vicente J, Johannesen L et al. Common genetic variant risk score is associated with drug-induced QT prolongation and torsade de pointes risk: a pilot study. Circulation 135(14), 1300–1310 (2017). •• The authors developed a genetic risk score that comprised 61 common variants derived from GWAS of baseline QT interval, and it explained a significant proportion of the variability in drug-induced QT prolongation.
  MedlineGoogle Scholar
• 78. Splawski I, Tristani-Firouzi M, Lehmann MH, Sanguinetti MC, Keating MT. Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nat Genet 17(3), 338–340 (1997).
  Medline CASGoogle Scholar
• 79. Sesti F, Goldstein SA. Single-channel characteristics of wild-type IKs channels and channels formed with two minK mutants that cause long QT syndrome. J Gen Physiol 112(6), 651–663 (1998).
  Medline CASGoogle Scholar
• 80. Bianchi L, Shen Z, Dennis AT et al. Cellular dysfunction of LQT5-minK mutants: abnormalities of IKs, IKr and trafficking in long QT syndrome. Hum Mol Genet 8(8), 1499–1507 (1999).
  Medline CASGoogle Scholar
• 81. Hoppe UC, Marbán E, Johns DC. Distinct gene-specific mechanisms of arrhythmia revealed by cardiac gene transfer of two long QT disease genes, HERG and KCNE1. Proc. Natl. Acad. Sci. USA 98(9), 5335–5340 (2001).
  Medline CASGoogle Scholar
• 82. Tinel N, Diochot S, Borsotto M, Lazdunski M, Barhanin J. KCNE2 confers background current characteristics to the cardiac KCNQ1 potassium channel. Embo. J. 19(23), 6326–6330 (2000).
  Medline CASGoogle Scholar
• 83. Albert CM, Nam EG, Rimm EB et al. Cardiac sodium channel gene variants and sudden cardiac death in women. Circulation 117(1), 16–23 (2008).
  Medline CASGoogle Scholar
• 84. Yang P, Kanki H, Drolet B et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 105(16), 1943–1948 (2002).
  Medline CASGoogle Scholar
• 85. Liu K, Yang T, Viswanathan PC, Roden DM. New mechanism contributing to drug-induced arrhythmia: rescue of a misprocessed LQT3 mutant. Circulation 112(21), 3239–3246 (2005).
  MedlineGoogle Scholar